The conventional management of patients with high-risk Philadelphia chromosome-negative (Ph-negative) myeloproliferative disorders (MPDs) revolves around the administration of cytoreductive agents such as hydroxyurea, anagrelide, and recombinant human interferon α (IFN-α). IFN-α has shown significant activity in the treatment of chronic myelogenous leukemia (CML) and Ph-negative MDPs. However, the response rates of IFN-α therapy frequently have been hampered by high dropout rates due to side effects and inconvenient dosing schedules. Pegylated (PEG) IFN-α is formulated by covalently attaching polymers of ethylene glycol of large molecular weight to the native IFN-α molecule. Such chemical modification increases serum half-life, decreases renal excretion, and results in prolonged patient exposure to PEG-IFN-α, thus allowing for weekly administration while maintaining acceptable toxicity, tolerability, and activity profiles. The lack of adequate therapies for patients with MPDs and the superior pharmacokinetic and pharmacodynamic profile of PEG-IFN-α relative to standard IFN-α has prompted the investigation of the activity and safety of PEG-IFN-α in patients with essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis. We summarize the available data on the use of PEG-IFN-α in patients with Ph-negative MPDs.
- Clinical trials
- Myeloproliferative disorders
- Pegylated interferon
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine